Aims and methods: To evaluate if the effects of longterm treatment with different antihypertensive drugs on left ventricular (LV) hypertrophy seen in meta-analysis could also be found in a cross-sectional study of elderly men, we investigated 584 70-year-old men with echocardiography of which 179 were treated for hypertension. Results: Men on antihypertensive treatment showed a significantly higher LV mass than normotensive men (143 ± 29 vs 132 ± 28 g/m 2 , P Ͻ 0.01), but no significant difference in LV mass was seen between men on one antihypertensive drug (n = 129) and those on two drugs (n = 47). Among the men on monotherapy, no differences in LV mass between the subjects who were treated with calcium-antagonists (142 ± 27 g/m 2 , n = 37),
Introduction
Several clinical trials have shown that antihypertensive therapy can reduce left ventricular (LV) hypertrophy in essential hypertension, measured either as LV mass or as LV wall thickness. [1] [2] [3] [4] In meta-analyses of prospective trials a significant difference between drug classes in the ability to reduce LV hypertrophy has been shown. 3, 4 Angiotensinconverting enzyme (ACE) inhibitors have been shown to reduce LV mass more than beat-blockers and diuretics, with calcium (Ca) channel blockers in between. Similar results were found for LV wall thickness. However, these findings are the results of meta-analysis of clinical trials with different inclusion and exclusion criteria and different durations of treatment in different populations. Furthermore, as most of these clinical trials were conducted in middle-aged subjects, it is not obvious that the results could be extrapolated to elderly hypertensives. The purpose of the present study was therefore to investigate the influence on LV hypertrophy of different antihpertensive therapies using a population study of 70-year-old men.
, n = 20) were found. Neither did blood pressure differ between these groups. Excluding subjects with coronary heart disease did not alter the results. Thiazides as monotherapy was uncommon in this population (n = 4) and therefore not evaluated. Conclusion: In a population sample of elderly men with hypertension, no differences in LV mass or blood pressure could be seen between subjects treated with ACEinhibitors, calcium-antagonists or beta-blockers as monotherapy. In meta-analysis of the effects of different antihypertensive therapies on regression of LV hypertrophy, ACE-inhibitors have shown the best results.
Subjects and methods

Study population
All men born between 1920-1924 and living in Uppsala were invited to a health survey in 1970-1973 (The Uppsala Primary Preventive Study) investigating risk factors for coronary heart disease. [5] [6] [7] Of the invited subjects 2322 participated (82%). These men were reinvestigated 10 years later (in 1980-1983) and at the 20-year follow-up (at the age of 70 years) an echocardiographic and Doppler examination was included. Outside this study most of the men were in the care of their general practitioner. The present study population consisted of the first 584 consecutive men of the original cohort attending the 20-year follow-up.
Hypertension was defined as a supine office systolic blood pressure у140 mm Hg and diastolic blood pressure у90 mm Hg or antihypertensive medication (at the investigation at the age of 70 years). The treatment for hypertension were in many cases initiated at the investigations at 50 or 60 years of age, although not all of the hypertensive men had hypertension also at the age of 50 or 60 years of age. Blood pressure was measured after at least 5 min rest in recumbent position using the phase V of the Korotkoff sound and the arm placed at heart level.
Of the initial 584 subjects, 305 were found to be normotensive and 279 were hypertensive (179 treated and 100 untreated) (Figure 1) . Of the subjects with treated hypertension, 129 were on monotherapy, 47 on two drugs and three were on three drugs. Of the subjects on monotherapy, 37 had Ca-blockers, 20 ACE-inhibitors, 66 beta-blockers (almost exclusively without intrinsic sympathomimetic effect), four were on diuretics and two on alpha-blockers. The mean duration of monotherapy was 7.5 years, being 8.1 years for beta-blockers, 6.3 years for Cablockers and 5.5 years for ACE-inhibitors (no significant difference between the drugs). Of the subjects on two drugs, the combination of a beta-blocker and a thiazide was most common.
Coronary heart disease defined by a hospital diagnosis of myocardial infarction or angina pectoris or a definitive Q wave on the ECG was seen in 91 subjects.
Subjects with cardiomyopathies, arrhythmias, atrioventricular block II or III or significant valvular disease were excluded from the study. Left ventricular (LV) volumes were calculated according to Teichholz formula 8 and from that ejection fraction (EF) was calculated. LV mass was determined from echocardiographical measurements of IVS, PW and LVEDD using the M-mode formula of Troy according to the recommendations of the American Society of Echocardiography. 9 The upper limit for LV mass/body surface area (BSA) was considered to be 150 g/m 2 according to data from the Framingham Heart Study. 10 A partition value of 0.44 was used for LV relative wall thickness according to Ganau et al. 11 Thus, LV geometry was considered normal if LV relative wall thickness was Ͻ0.44 and LV mass/BSA Ͻ150 g/m 2 . A normal LV mass/BSA with increased LV relative wall thickness was denoted LV concentric remodelling according to Ganau et al, 11 while a hypertrophied left ventricle was denoted eccentric if the relative wall thickness was normal, and concentric if the relative wall thickness was increased.
As measurement of LV diastolic function, the filling of left ventricle (mitral flow velocities) was used. The LV diastolic filling pattern of the mitral inflow was obtained from the apical transducer position with the sample volume between the tips of the mitral leaflets during diastole. The peak velocity of the early rapid filling wave (E wave) and the peak velocity of atrial filling (A wave) were recorded and the E to A ratio (E/A) was calculated. Left ventricular isovolumic relaxation time (IVRT) was measured as the time between aortic valve closure and the start of mitral flow using the Doppler signal from the area between the LV outflow tract (LVOT) and mitral flow.
The LVOT diameter was obtained from a parasternal long axis view, while the flow velocity integral (FVI) was determined from the apical window with the sample volume at approximately the same level as the diameter measurement was done. From these two variables, stroke volume (SV) was calculated as × LVOT 2 /4 × FVI. As further measurements of systolic function the LV wall motion score index was determined. The wall motion score index was calculated as the mean score in a 16-segment model of the left ventricle, using 1 = normal wall motion, 2 = hypokinetic wall motion, 3 = akinetic and 4 = paradoxical wall motion. 12 To correct for differences in body constitution, stroke volume, cardiac output and LV mass were divided by BSA giving stroke index (SI), cardiac index and LV mass/BSA. Total peripheral resistance index (TPRI) was calculated from mean arterial pressure (MAP) and cardiac index (CI) as 80 × (MAP−3)/CI (dyn s cm 5 m 2 10
3 ). All examinations were performed with the subjects in the standard left lateral position and in expiratory apnea or during quiet breathing. The best five cardiac beats were chosen and the average of these was calculated.
All measurements were done on-line and stored in the computer of the ultrasonic unit for later print out. Both the performance and the reading of the 501 images were done by one experienced physician (BA) unaware of the clinical data of the subjects.
Reproducibility study
Investigations were repeated in 22 randomly selected subjects approximately 1 month after the initial investigation. Thus, intra-observer variability measured as the difference between the two measurements divided by the first measurement was for the dimensions LA 5%, IVS 10%, LVEDD 3%, PW 9%, LVESD 6%, LVOT 3%, SI 9%, LV mass/BSA 14%, EF 9%. For the Doppler measurements the variability was FVI 8%, E 12%, A 11%, IVRT 8% and HR 6%.
Statistical analysis
Factorial ANOVA was used to calculate differences in means between the groups. Dunnett's test was used for post hoc analyses. Chi-square tests were used to determine differences in proportions between groups. The Kruskal-Wallis test was used for non-normally distributed variables, such as LV wall motion score index. Two-tailed significance values were given with P Ͻ 0.05 regarded as significant.
Results
Subjects with antihypertensive therapy showed significantly higher blood pressure, total peripheral resistance as well as LV mass/BSA (143 ± 29 s.d. vs 132 ± 28 g/m 2 ) than the normotensive group ( Table  1) . The elevated blood pressure in the group with antihypertensive therapy was already seen at the age of 50 and 60 years (Table 1) . Subjects with untreated hypertension showed significantly higher levels of Abbreviations: HR = heart rate at the age 70 years, SBP70, SBP60, SBP50 = systolic blood pressure at the age of 70, 60 and 50 years, DBP70, DBP60, DBP50-diastolic blood pressure at the age of 70, 60 and 50 years, SBP70 24 h. DBP70 24 h = systolic and diastolic blood pressure during 24 hours, TPRI = total peripheral resistance, LV mass = left ventricular mass, RWT = relative wall thickness. ***P Ͻ 0.001, **P Ͻ 0.01, *P Ͻ 0.05 compared with the normotensive group.
both systolic and diastolic blood pressures at the age of 70 than those treated with one antihypertensive drug, and for diastolic blood pressure also for those treated with two drugs (all P Ͻ 0.0001). At the age of 50 and 60 years the untreated group already had significantly higher blood pressure than the normotensive group, but at this time the blood pressure was lower than in the group that was treated for hypertension at age 70. No significant difference in LV mass/BSA was seen between subjects with one and those with two antihypertensive drugs (141 ± 27 vs 147 ± 32 g/m 2 ) ( Table 1) . A significant (P Ͻ 0.0002) difference in the LV geometric patterns was seen when normotensive subjects were compared to those on antihypertensive treatment with one or two drugs. An increased number of subjects with two antihypertensive drugs showed eccentric LV hypertrophy (38%), and there was also a tendency for those with monotherapy to show eccentric LV hypertrophy (21%), when compared with the normotensive group (14%) ( Table 1) .
Although coronary heart disease was more common in hypertensive subjects with both one and two drugs (22% and 28%) than in the normotensive group (15%) (P Ͻ 0.01), only subjects with two antihypertensive drugs had a significantly (P Ͻ 0.05) higher LV score than the normotensive subjects. No significant differences were seen however in ejection fraction, stroke index or cardiac index between the normotensive subjects and the subjects on antihypertensive therapy (Table 2) .
Subjects with untreated hypertension was the only hypertensive group that showed significant differences in any of the LV diastolic variables (an increased A-wave and a decreased E/A-ratio), when compared to the normotensive group (Table 2) .
Among subjects on antihypertensive monotherapy, there were no differences in LV mass/BSA between those treated with calcium-antagonists, beta-blockers or ACE-inhibitors (142 ± 27, 140 ± 29 and 142 ± 33 g/m 2 respectively) ( Figure 2 ). Neither were any differences in office blood pressures at the ages of 50, 60 or 70 years or 24-h ambulatory blood pressure at age 70, found between these three groups. No significant differences between the monotherapies regarding the prevalence of coronary heart disease was found (Ca-antagonists 16%, ACEinhibitors 15%, beta-blockers 28%) and a similar LV mass was seen in the three groups when only subjects without coronary heart disease were included (139 ± 24, 140 ± 30 and 144 ± 29 g/m 2 respectively). No relationships between the change in blood pressure from age 50 to 70 and LV mass at age 70 were seen in any of the groups (r = 0.02-0.07) with monotherapy. There were no significant differences in any of the investigated indices of LV systolic or diastolic function between the monotherapies, with the exception of a prolongation of IVRT in the group treated with Ca-antagonists (Table 3) . Neither was any significant difference in the LV geometric pattern seen between the three monotherapies ( Table  4 ). The subjects on three antihypertensive drugs (n = 3) or those on thiazids or alpha-blockers as monotherapy (n = 4 and n = 2), were too few to evaluate.
Discussion
The main finding in this population-based study is that blood pressure and LV mass were similar in elderly male hypertensives treated with monotherapy with either beta-blockade, Ca-blockade or ACEinhibitors.
In a population study like this running for 20 years, the type of antihypertensive therapy was not randomised, but the choice of the corresponding general practitioner was. It can not therefore be regarded as a clinical trial, but could serve as a tool to investigate which effects these drugs induce on the heart during long-term use at the population level. In that sense the results from a population study like this are of importance, although not fulfilling the criteria for an informative trial suggested by Devereux and Dahlkö f. 13 Several factors might explain the difference between the results from the meta-analysis 3,4 and the present findings. First, the meta-analysis were based on a number of clinical trials. In clinical trials the compliance to a prescribed medication is generally better than that seen in a general population and the drugs might therefore be more effective to induce regression of LV hypertrophy in clinical trials. Although no formal evaluation of adherence to antihypertensive treatment was performed in our population, the fact that mean office diastolic blood pressure was below 90 mm Hg in the group with monotherapy and lower than the blood pressure in the untreated hypertensive group suggests that adherence to treatment was good. Furthermore, these subjects regularly attending this health survey for 20 years probably represent a selection of sub- Abbreviations: LA = left atrium dimension, IVS = interventricular septal thickness, LVEDD = left ventricular end-diastolic diameter, PW = left ventricular posterior wall thickness, EF = ejection fraction, LV score index = left ventricular score index, SI = stroke index, CI = cardiac index, E = velocity of early diastolic filling wave (mitral Doppler), A = velocity of late diastolic (atrial) filling wave (mitral Doppler), IVRT = isovolumic relaxation time. ***P Ͻ 0.001, **P Ͻ 0.01, *P Ͻ 0.05 compared with the normotensive group. Abbreviations: HR = heart rate at the age of 70 years, SBP70, SBP60, SBP50 = systolic blood pressure at the age of 70, 60 and 50 years, DBP70, DBP60, DBP50 = diastolic blood pressure at the age of 70, 60 and 50 years, SBP70 24 h, DBP70 24 h = systolic and diastolic blood pressure during 24 hours, TPRI = total peripheral resistance, LV mass = left ventricular mass, RWT = relative wall thickness ***P Ͻ 0.001, **P Ͻ 0.01, *P Ͻ 0.05 compared with the normotensive group.
jects interested in their health and are therefore prone to adhere to a given medication. Second, most studies included in the meta-analysis were conducted in middle-aged populations. With age, LV mass increases. The reason for this is not fully understood. Increased fibrosis, increased peripheral resistance etc may play a role. This process may not be influenced by antihypertensive treatment. A substantial number of subjects with LV hypertrophy was found even among healthy, normotensive subjects in our population.
14 Also the activity of the renin-angiotensin system may be lower in elderly men making ACE-inhibitors less effective. Also nutritional factors, such as weight and sodium intake, and physical activity may have counteracted the result of the antihypertensive treatment in the elderly. Therefore data of treatment effects based on trials in middle-aged subjects may not be extrapolated to elderly subjects, although experimental studies have suggested a benefical role for ACE-inhibition also in a fibrotic myocardium. 15 Unfortunately, no echocardiography was available in Uppsala at the beginning of 1970 when this study started, making a comparison of LV mass over the years impossible.
However, in the present population blood pressure data from the past 20 years were available. These longitudinal data show that the blood pressure load had been similar over this period in the three groups with different monotherapies. Furthermore, conclusion regarding LV mass was not confounded by any differences in the prevalence of coronary heart 504 disease between the groups with monotherapy. The similar effect on LV geometry in the three groups with monotherapy is further strengthened by the finding of a similar E/A ratio in the groups, as LV diastolic function generally is affected by LV hypertrophy. The only deviation in this respect was a prolonged IVRT in the calcium-antagonist group, which might be a direct effect of calcium-channel blockade.
Hypertensive subjects treated with two agents did not show a reduced LV mass/BSA compared to those on monotherapy. According to the blood pressure data a more aggressive form of hypertension is probably seen in this group, an assumption supported by the fact that coronary heart disease was most prevalent in this group. Also eccentric LV hypertrophy, the form of LV hypertrophy possibly representing a damaged left ventricle, was most often found in the subjects on two antihypertensive drugs.
The hypertensive subjects without treatment represent a group with mild hypertension that has developed mainly during the preceding decade. In this group only a minor insignificant elevation in LV mass was seen, but the lowest E/A ratio was found demonstrating that LV diastolic dysfunction is an early finding in hypertensive disease also in the elderly, and not only in middle-aged hypertensives as previously reported. [16] [17] [18] The fact that both a lower E/A ratio and a lower LV mass, but a higher blood pressure, were found in this group when compared to the treated hypertensives highlight the influence of a raised blood pressure on the LV diastolic function. Heart rate did not differ significantly between the subgroups on different monotherapies or between the normotensives and the subgroups on monotherapies, but the group with untreated hypertension showed the highest heart rate being significantly different when compared with both the normotensives and the subgroups with one or two drugs. However, taking this into account in the statistical analysis the significantly lower E/A ratio in the group with untreated hypertension still persisted, probably as a result of the hypertension itself.
In summary, in a population sample of elderly men with hypertension, no differences in LV mass or blood pressure could be seen between subjects treated with ACE-inhibitors, calcium-antagonists or beta-blockers as monotherapy.
